Innovent Biologics Inc (6IB) — Financial Flexibility Index
Innovent Biologics Inc (6IB) has a Financial Flexibility Index of 0.00x as of June 2023. Free cash flow of €-12.49 Million (operating CF €-311.45 Million minus capex €298.95 Million) represents 0% of total liabilities (€7.11 Billion). Check Innovent Biologics Inc (6IB) strategic asset index to assess the company's strategic physical and investment asset allocation.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Innovent Biologics Inc Financial Flexibility Index (2016–2025)
Historical Financial Flexibility Index trend for Innovent Biologics Inc across 10 annual periods. See how liquid is Innovent Biologics Inc's working capital to evaluate short-term liquidity relative to the company's equity base.
Annual Financial Flexibility Index for Innovent Biologics Inc (2016–2025)
Year-by-year free cash flow to debt coverage for Innovent Biologics Inc. For the full company profile including market capitalisation, see 6IB market cap.
| Year | Flexibility Index | Free Cash Flow (EUR) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.59x | €10.68 Billion | €10.00 Billion | €17.99 Billion | ▲ +68.4% |
| 2024 | 0.35x | €2.99 Billion | €1.29 Billion | €8.48 Billion | ▲ +86.6% |
| 2023 | 0.19x | €1.53 Billion | €147.81 Million | €8.10 Billion | ▲ +341.4% |
| 2022 | -0.08x | €-537.07 Million | €-1.92 Billion | €6.86 Billion | ▲ +51.7% |
| 2021 | -0.16x | €-959.21 Million | €-2.02 Billion | €5.91 Billion | ▼ -373.3% |
| 2020 | 0.06x | €181.33 Million | €-307.69 Million | €3.06 Billion | ▲ +111.3% |
| 2019 | -0.52x | €-1.30 Billion | €-1.66 Billion | €2.47 Billion | ▼ -44.0% |
| 2018 | -0.36x | €-699.09 Million | €-1.01 Billion | €1.92 Billion | ▼ -270.5% |
| 2017 | -0.10x | €-401.30 Million | €-492.27 Million | €4.08 Billion | ▼ -21.9% |
| 2016 | -0.08x | €-304.55 Million | €-362.99 Million | €3.77 Billion | — |